Astellas
Amgen moves into Japanese market with Astellas deal
May 29, 2013Sales and Marketing Amgen, Astellas, Vectibix, Zhejiang
Amgen and Astellas have announced a new collaboration that will see them launch five new medicines in Japan from 2016, …
Orphan drug for Astellas
May 29, 2013Sales and Marketing Astellas, Isavuconazole, Orphan
The FDA has granted orphan designation to one of Astellas’ Phase III drugs designed to treat potentially life-threatening fungal infections …
Pulse mistake costs Astellas
March 15, 2013Medical Communications, Sales and Marketing ABPI, Astellas, PMCPA, pulse
A mistake by medical journal Pulse has landed Astellas Pharma in hot water with the PMCPA, enforcers of the ABPI …
Astellas appoints VP of Scientific and Medical Affairs
November 9, 2012Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Jeffrey Bloss
Astellas has announced Jeffrey Bloss has joined the company as vice president of its Scientific and Medical Affairs (ASMA) division. …
Astellas announces compliance officer for the Americas
October 26, 2012Manufacturing and Production, Research and Development, Sales and Marketing Astellas, McCauley
Astellas recently named J. Patrick McCauley Jr, a longtime pharmaceutical industry veteran and Astellas employee, to the post of Regional …
Astellas appoints Jo Underhill as Sales and Marketing director
September 14, 2012Business Services, Research and Development, Sales and Marketing Astellas, Jo Underhill
Astellas Pharma has appointed Jo Underhill as Sales and Marketing director, Urology/Dermatology, completing its UK management team. Reporting directly to …
Astellas Pharma Europe appoints new senior director
August 14, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Susan Wood
Astellas Pharma Europe has appointed Dr Susan Wood as senior director, Market Access. Formerly senior brand director of APEL’s Pain Management …
FDA approves Astellas’ leaky bladder drug
July 3, 2012Sales and Marketing Astellas, FDA, Myrbetriq, bladder, urology
The FDA has approved Astellas’ new overactive bladder disorder drug Myrbetriq. Myrbetriq (mirabegron), the first drug in its class, works …
Astellas submits new prostate cancer drug to EMA
June 28, 2012Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide
Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …
Prostate cancer drug extends life after chemotherapy
March 29, 2012Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer
Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …
Astellas adds two senior executives at US site
December 5, 2011Business Services, Manufacturing and Production, Sales and Marketing Astellas
Astellas’ US subsidiary Agensys has appointed Frank Hudson as vice president of finance, and Wolfgang Noe as vice president of …
Astellas abandons oral anticoagulant darexaban
September 30, 2011Research and Development Astellas, Eliquis, Xarelto, darexaban
Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
Ken Jones appointed head of Astellas Europe
April 13, 2011Astellas, Ken Jones
Astellas has appointed Ken Jones as its president and chief executive in Europe. Jones had been the chief operating officer …
Japan’s pharma industry pledges to maintain medicines supply
March 17, 2011Sales and Marketing Astellas, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Japan, earthquake
Pharmaceutical firms in Japan have escaped the very worst of the devastation caused by the earthquake and tsunami, and have …
Astellas to commercialise new kidney cancer drug in Europe
February 21, 2011Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib
Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …
Latest content
FibroFind appoints Lee Borthwick as CEO
